(R,S)-ethyl 3-amino-3-(quinolin-3-yl)propanoate | 188812-74-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (R,S)-ethyl 3-amino-3-(quinolin-3-yl)propanoate
• 英文别名: ethyl 3-amino-3-(3-quinolinyl)propionate；Ethyl 3-amino-3-quinolin-3-ylpropanoate
• CAS: 188812-74-0
• 化学式: C₁₄H₁₆N₂O₂
• 分子量: 244.293
• InChiKey: LHXLIPYYKOVEJT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  65.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (R,S)-ethyl 3-amino-3-(quinolin-3-yl)propanoate 在 硫酸氢铵 、 phosphate buffer 作用下， 反应 20.0h， 生成 3-<<4-<<4-(aminoiminomethyl)phenyl>amino>-1,4-dioxobutyl>amino>-5-hexenoic acid
  参考文献：
  名称：

  Potent in Vitro and in Vivo Inhibitors of Platelet Aggregation Based Upon the Arg-Gly-Asp Sequence of Fibrinogen. (Aminobenzamidino)succinyl (ABAS) Series of Orally Active Fibrinogen Receptor Antagonists

  摘要：

  Our initial orally active fibrinogen receptor antagonist benzamidinopentanoyl (BAP) series which was discovered through truncation of our iv antiplatelet agent (SC-52012) demonstrated modest oral activity in canine studies (ethyl [5-(4-amidinophenyl)pentanoyl]3-3-amino-3 pyridyl)propionate, 1e). Introduction of an amide bond adjacent to the benzamidine led to a novel series with an (aminobenzamidino)succinyl (ABAS) Arg-Gly surrogate that had improved in vitro potency (5-17 times) relative to the BAP series. Four ester prodrug/acid active metabolite pairs (2a/2e, 60a/60e, 62a/62e, 63a/63e) from the ABAS series which varied in their 3-substituent on the beta-amino ester ''aspartate mimetic'' were prepared in enantiomerically enriched form (>95:5), and they were evaluated in canine studies for their ability to block collagen-induced aggregation in platelet-rich plasma, the elimination profile (t(1/2) beta-phase), repeated oral dosing studies, and oral systemic availability. Of the four ester prodrug/acid active metabolite pairs, 2e/2a (SC-54684A/SC-54701A) had the most favorable properties in the above studies with an IC50 = 67 +/- 5 nM (dog platelet-rich plasma, collagen), t(1/2) beta = 1.6 h tester) and 6.5 h (acid), no adverse effects upon repeated dosing, and a drug oral systemic availability of 62% (area under curve (AUG) of acid 2a (drug) following ig administration of ester 2e (prodrug, 2.5 mg/kg) divided by AUC of acid 2a (drug) following iv administration of ester 2e (prodrug, 2.5 mg/kg) as determined by HPLRC). In further pharmacokinetic studies using nonlabeled 2e/2a, the oral systemic availability tester 2e ig/ester 2e iv) of 2e was measured to be in the range of 44.7-53.0%. The more biologically relevant oral systemic availability tester 2e ig/acid 2a iv) of 2e was found to be in the range of 22.0-26.4%. A pharmacophore model. based on inhibitors from several different benzamidine classes including 2a (ABAS class) was developed using a combination of molecular modeling (MM2) and pharmacophore identification (APOLLO) methods.

  DOI：

  10.1021/jm00013a014
• 作为产物：
  描述：

  3-喹啉甲醛 在 乙酸铵 、 氯化亚砜 作用下， 以 异丙醇 为溶剂， 反应 7.0h， 生成 (R,S)-ethyl 3-amino-3-(quinolin-3-yl)propanoate
  参考文献：
  名称：

  新型丙二酰胺衍生物作为αvβ3拮抗剂。3-（3-吲哚-1-基-1-基-3-氧代丙酰基）氨基丙酸的合成和对玻连蛋白与αv beta 3相互作用的评价。

  摘要：

  为了找到新的整联蛋白αvbeta3拮抗剂，我们选择了SC65811及其胍类似物（1）作为先导化合物。SC65811甘氨酸部分的修饰导致了一系列新的丙二酰胺衍生物，这些衍生物表现出alphavbeta3抑制活性。其中，（R，S）-3- [3- [6-（3-苄基脲基）吲哚-1-基] -3-氧代丙酰基氨基] -3-（吡啶-3-基）丙酸（43a）未显示相对于alphaIIbbeta3，alpha5beta1和alphavbeta5，IC50值仅为3.0 nM的有效活性，而且对alphavbeta3的选择性也很好，IC50值分别为19,000、11,000和14 nM。此外，优化43a导致最有效的alphavbeta3拮抗剂（R，S）-3-（3- [6-[（4,5-二氢-1H-咪唑-2-基）氨基]吲哚-1-基] -3-氧代丙酰基氨基）-3-（喹啉-3-基）丙酸（431），IC50值为0.42 nM。

  DOI：

  10.1248/cpb.49.1420

文献信息

• [EN] INTEGRIN RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RECEPTEUR DE L'INTEGRINE
  申请人：MERCK & CO., INC.

  公开号：WO1999031061A1

  公开（公告）日：1999-06-24

  (EN) The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors $g(a)$g(n)$g(b)3, $g(a)$g(n)$g(b)5, and/or $g(a)$g(n)$g(b)6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.(FR) L'invention concerne des composés et des dérivés desdits composés, leurs synthèses et leur utilisation comme antagonistes du récepteur de l'intégrine. Plus particulièrement, les composés de l'invention sont des antagonistes des récepteurs $g(a)$g(n)$g(b)3, $g(a)$g(n)$g(b)5 et/ou $g(a)$g(n)$g(b)6 de l'intégrine, et conviennent comme inhibiteurs de la résorption osseuse, produits de traitement ou de prévention de l'ostéoporose, de traitement des plaies, ou inhibiteurs de la resténose vasculaire, de la rétinopathie diabétique, de la dégénérescence maculaire, de l'angiogenèse, de l'athérosclérose, de l'inflammation, de maladies virales, de la croissance tumorale et de la métastase.

  本发明涉及化合物及其衍生物，它们的合成以及它们作为整合素受体拮抗剂的用途。更具体地说，本发明的化合物是整合素受体$g(a)$g(n)$g(b)3，$g(a)$g(n)$g(b)5和/或$g(a)$g(n)$g(b)6的拮抗剂，可用于抑制骨吸收，治疗和预防骨质疏松症，抑制血管再狭窄，糖尿病视网膜病变，黄斑变性，血管生成，动脉粥样硬化，炎症，伤口愈合，病毒性疾病，肿瘤生长和转移。
• Integrin receptor antagonists
  申请人：——

  公开号：US20020010176A1

  公开（公告）日：2002-01-24

  The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors &agr;v&bgr;3, &agr;v&bgr;5, and/or &agr;v&bgr;6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.

  本发明涉及化合物及其衍生物，其合成以及它们作为整合素受体拮抗剂的用途。更具体地说，本发明的化合物是整合素受体αvβ3、αvβ5和/或αvβ6的拮抗剂，可用于抑制骨吸收，治疗和预防骨质疏松症，抑制血管再狭窄，糖尿病视网膜病变，黄斑变性，血管生成，动脉粥样硬化，炎症，伤口愈合，病毒性疾病，肿瘤生长和转移。
• INTEGRIN RECEPTOR ANTAGONISTS
  申请人：Merck & Co., Inc. (a New Jersey corp.)

  公开号：EP1040098B1

  公开（公告）日：2005-04-27
• US6048861A
  申请人：——

  公开号：US6048861A

  公开（公告）日：2000-04-11
• US6297249B1
  申请人：——

  公开号：US6297249B1

  公开（公告）日：2001-10-02